Skip to content
10-Q

Quarterly Report

DIAMEDICA THERAPEUTICS INC. DMAC

0001437749-26-015220

← back to feed
Filed
May 6, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · May 4, 2026 53.88M sh
Capex Q1 2026 · Mar 31, 2026 $8K
Capex Q1 2026 · Mar 31, 2025 $12K
Operating Cash Flow Q1 2026 · Mar 31, 2026 −$9.08M
Operating Cash Flow Q1 2026 · Mar 31, 2025 −$7.15M
Cash And Equivalents Q1 2026 · Mar 31, 2026 $4.87M
Cash And Equivalents Q1 2026 · Dec 31, 2025 $15.65M
Stockholders Equity Q1 2026 · Mar 31, 2026 $47.24M
Stockholders Equity Q1 2026 · Dec 31, 2025 $56.11M
Stockholders Equity Q1 2026 · Mar 31, 2025 $33.95M
Stockholders Equity Q1 2026 · Dec 31, 2024 $40.72M
Current Liabilities Q1 2026 · Mar 31, 2026 $5.75M
Current Liabilities Q1 2026 · Dec 31, 2025 $5.13M
Current Assets Q1 2026 · Mar 31, 2026 $52.36M
Current Assets Q1 2026 · Dec 31, 2025 $60.63M
Total Assets Q1 2026 · Mar 31, 2026 $53.08M
Total Assets Q1 2026 · Dec 31, 2025 $61.37M
Eps Basic Q1 2026 · Mar 31, 2026 −$0.19
Eps Basic Q1 2026 · Mar 31, 2025 −$0.18
Sga Expense Q1 2026 · Mar 31, 2026 $2.5M
Sga Expense Q1 2026 · Mar 31, 2025 $2.49M
Rd Expense Q1 2026 · Mar 31, 2026 $7.99M
Rd Expense Q1 2026 · Mar 31, 2025 $5.66M
Net Income Q1 2026 · Mar 31, 2026 −$10.04M
Net Income Q1 2026 · Mar 31, 2025 −$7.71M
Operating Income Q1 2026 · Mar 31, 2026 −$10.48M
Operating Income Q1 2026 · Mar 31, 2025 −$8.14M